Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Haskins

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Regulatory Peptides|February 1, 1982
Evidence for vasoactive intestinal polypeptide (VIP) altering the firing rate of preoptic, septal and midbrain central gray neuronsJ T Haskins, W K Samson, R L Moss
The Journal of Clinical Psychiatry|September 15, 1999
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorderJ R Davidson, R L DuPont, D Hedges, et al.
The American Journal of Psychiatry|June 1, 2000
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorderK Rickels, M H Pollack, D V Sheehan, et al.
Endocrinology|March 1, 1981
Iontophoresis of morphine into the arcuate nucleus: effects on dopamine concentrations in hypophysial portal plasma and serum prolactin concentrationsJ T Haskins, G A Gudelsky, R L Moss, et al.
European Journal of Pharmacology|September 24, 1985
DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activityJ T Haskins, J A Moyer, E A Muth, et al.
JAMA|June 24, 2000
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trialA J Gelenberg, R B Lydiard, R L Rudolph, et al.
Journal of Medicinal Chemistry|May 1, 1989
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agentsM Abou-Gharbia, J A Moyer, U Patel, et al.
Biochemical Pharmacology|December 15, 1986
Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivativeE A Muth, J T Haskins, J A Moyer, et al.
European Journal of Pharmacology|June 24, 1993
WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptorsA Fletcher, D J Bill, S J Bill, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Regulatory Peptides|February 1, 1982
Evidence for vasoactive intestinal polypeptide (VIP) altering the firing rate of preoptic, septal and midbrain central gray neuronsJ T Haskins, W K Samson, R L Moss
The Journal of Clinical Psychiatry|September 15, 1999
Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorderJ R Davidson, R L DuPont, D Hedges, et al.
The American Journal of Psychiatry|June 1, 2000
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorderK Rickels, M H Pollack, D V Sheehan, et al.
Endocrinology|March 1, 1981
Iontophoresis of morphine into the arcuate nucleus: effects on dopamine concentrations in hypophysial portal plasma and serum prolactin concentrationsJ T Haskins, G A Gudelsky, R L Moss, et al.
European Journal of Pharmacology|September 24, 1985
DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activityJ T Haskins, J A Moyer, E A Muth, et al.
JAMA|June 24, 2000
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trialA J Gelenberg, R B Lydiard, R L Rudolph, et al.
Journal of Medicinal Chemistry|May 1, 1989
Synthesis and structure-activity relationship of substituted tetrahydro- and hexahydro-1,2-benzisothiazol-3-one 1,1-dioxides and thiadiazinones: potential anxiolytic agentsM Abou-Gharbia, J A Moyer, U Patel, et al.
Biochemical Pharmacology|December 15, 1986
Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivativeE A Muth, J T Haskins, J A Moyer, et al.
European Journal of Pharmacology|June 24, 1993
WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptorsA Fletcher, D J Bill, S J Bill, et al.
Pageof 2